Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 9 of 9 entries
View as:

Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)

Phase: N/A Priority: Normal
NCT ID: NCT05607810 Org: User:
Start: 08/10/22 End: 04/30/26 Due: 04/30/27

Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT02168686 Org: User:
Start: 11/28/17 End: 08/29/19 Due: 08/29/20

Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]

Phase: N/A Priority: Normal
NCT ID: NCT04645212 Org: User:
Start: 12/14/20 End: 06/30/25 Due: 06/30/26

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration

Phase: N/A Priority: Normal
NCT ID: NCT06856577 Org: User:
Start: 02/28/25 End: 03/25/30 Due: 03/25/31

Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]

Phase: N/A Priority: Normal
NCT ID: NCT05536973 Org: User:
Start: 08/23/22 End: 08/31/28 Due: 08/31/29

ADVM-022 Intravitreal Gene Therapy for Wet AMD

Phase: N/A Priority: Normal
NCT ID: NCT03748784 Org: User:
Start: 11/14/18 End: 06/22/22 Due: 06/22/23

A Study to Characterize the Cardiac Phenotype of Individuals With Friedreich's Ataxia (CARFA Study)

Phase: N/A Priority: Normal
NCT ID: NCT02840669 Org: User:
Start: 07/31/16 End: 09/30/18 Due: 09/30/19

Long-Term Follow-up Study of ADVM-043

Phase: N/A Priority: Normal
NCT ID: NCT03804021 Org: User:
Start: 12/27/18 End: 12/06/21 Due: 12/06/22

ADVM-022 Intravitreal Gene Therapy for DME

Phase: N/A Priority: Normal
NCT ID: NCT04418427 Org: User:
Start: 05/28/20 End: 11/22/22 Due: 11/22/23